Skip to main content
SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD logo

SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD — Investor Relations & Filings

Ticker · 000078 ISIN · CNE000000X95 LEI · 300300J4GCOV7CYQTB51 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,619 across all filing types
Latest filing 2021-01-11 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 000078

About SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD

https://www.neptunusbio.com

Shenzhen Neptunus Bioengineering Co., Ltd. is a comprehensive healthcare enterprise focused on the research, development, manufacturing, and distribution of pharmaceutical products. The company operates across the entire industry value chain, including the production of chemical drugs, biological preparations, and traditional Chinese medicines. Its portfolio extends to medical devices and health supplements. A significant component of its operations involves a large-scale pharmaceutical distribution network and a nationwide retail pharmacy chain. The company emphasizes innovation in biotechnology and maintains modern production facilities to support its diverse product lines. By integrating R&D with a robust logistics and retail infrastructure, it provides a wide range of healthcare solutions to medical institutions and consumers.

Recent filings

Filing Released Lang Actions
关于药品“诺氟沙星胶囊”通过一致性评价的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the approval of a pharmaceutical product's consistency evaluation by the National Medical Products Administration. It includes details about the drug, its registration, and the impact on the company. The document is short (993 characters) and serves as a formal announcement of regulatory approval rather than a financial report or detailed management discussion. There is no financial data, no mention of annual or quarterly results, no board changes, no voting results, or other report types. It fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement about product approval and company disclosure compliance.
2021-01-11 Chinese
关于股东部分股份解押及质押的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the partial release and new pledging of shares by the controlling shareholder of Shenzhen Haiwang Bioengineering Co., Ltd. It details the number of shares released from pledge, newly pledged shares, pledge ratios, pledge purposes, and confirms no major risks or violations related to these pledges. The document includes tables of shareholding and pledge data, explanations about the pledge's impact, and related financial data of the controlling shareholder. There is no indication that this is a full financial report, earnings release, or management discussion. It is a specific update on share pledging activities by a major shareholder, which fits the category of Capital/Financing Update (CAP). The document length is under 5,000 characters, but it contains substantive data about share pledging, not just a notice of report publication or certification. Therefore, it is not a Report Publication Announcement or Regulatory Filing. Hence, the best classification is Capital/Financing Update (CAP).
2021-01-03 Chinese
关于对外担保进展暨解除对外担保的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from Shenzhen Haiwang Bioengineering Co., Ltd. regarding the progress and release of external guarantees. It details the company's guarantee obligations to another company and the status of these guarantees being fully released. The document is short (844 characters) and focuses on a specific corporate event related to guarantees, not financial results, management changes, or regulatory certifications. It is not a full financial report, audit, or earnings release. The content fits best with a regulatory announcement about corporate guarantees, which does not fall under more specific categories like capital updates or management changes. Therefore, it is classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous corporate announcements that do not fit other categories.
2020-12-30 Chinese
关于2020年度应兑付债券已全部按期偿还完毕的自愿性信息披露公告
Capital/Financing Update Classification · 95% confidence The document is a voluntary disclosure announcement regarding the full repayment of bonds due in 2020 by Shenzhen Haier Bioengineering Co., Ltd. It details the repayment of specific bond issues, repayment amounts, and references previous related announcements. The document is short (1005 characters) and serves as an update on financing activities, specifically bond repayments. It does not contain financial statements or detailed financial analysis but rather informs about capital structure changes and debt repayment completion. Therefore, it fits best under Capital/Financing Update (CAP).
2020-12-25 Chinese
关于收到《中国证监会行政许可项目审查二次反馈意见通知书》的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from Shenzhen Haiwang Bioengineering Co., Ltd. regarding receipt of a second feedback notice from the China Securities Regulatory Commission (CSRC) about the administrative licensing review of the company's non-public stock issuance application. It states the company must respond within 30 working days and that the approval is still pending, indicating ongoing regulatory review. The document is short (727 characters) and serves as a regulatory update on the status of a capital raising approval process, not the actual report or financial data. It does not contain financial statements or detailed analysis but is an announcement of regulatory feedback related to financing activities. Therefore, it fits best under Capital/Financing Update (CAP).
2020-12-11 Chinese
关于控股子公司变更注册资本的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the change in registered capital of a controlling subsidiary of the company. It includes details about the subsidiary, the change in capital amount, shareholder structure before and after the change, and the impact of this change. It references a board meeting resolution approving the change. The document is relatively short (1862 characters) and is an announcement of a corporate action related to capital structure but does not contain financial statements or detailed financial analysis. It is not a full financial report, audit report, or earnings release. It is not a report publication announcement since it contains substantive information about the capital change itself. The content fits best with the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes.
2020-12-09 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.